Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The prosaposin-progranulin complex is a molecular assembly formed by the physical interaction between prosaposin (PSAP) and progranulin (PGRN). This interaction is crucial for the delivery of each protein to the lysosome and has significant implications in neurodegenerative diseases. PSAP facilitates PGRN’s targeting to lysosomes. Both proteins are critical for maintaining normal degradative activity within lysosomes. Mutations or deficiencies affecting either component disrupt trafficking/function leading to accumulation of undegraded substrates—a hallmark in FTLD or NCL pathology. Stabilizing this complex pharmacologically may offer therapeutic benefits against neurodegeneration.
Augmenting or stabilizing the prosaposin-progranulin complex to enhance progranulin’s half-life/functionality in brain tissue
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prosaposin-Progranulin Complex (PSAP-PGRN Complex).